Current management strategies for the treatment and prevention of cytomegalovirus infection in solid organ transplant recipients

Rima Abu-Nader, Robin Patel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) infection in solid organ transplantation is associated with significant morbidity and mortality. Primary infection, secondary infection or superinfection may occur in this setting. Progression to disease may ensue with development of symptoms, with or without organ involvement. The mainstay of treatment of CMV disease is intravenous ganciclovir. Aside from protective organ matching and use of CMV-seronegative blood products, methods of preventing CMV infection and disease include passive immunization with immunoglobulins, vaccination, and prophylaxis with antiviral agents such as aciclovir, oral or intravenous ganciclovir, and oral valaciclovir. A promising subunit vaccine is currently being investigated. Pre-emptive therapy is a form of prevention that is based either on the early detection of CMV or targeting of transplant recipients with risk factors for CMV. New sensitive laboratory assays, including the pp65 antigenaemia assay, qualitative, quantitative and reverse-transcription polymerase chain reaction assays, hybridization assays, and nucleic acid sequence-based assays have the ability to detect early CMV replication before disease becomes evident. These assays are being used as prospective surveillance tests, with pre-emptive therapy initiated when they become positive or demonstrate an increasing titre.

Original languageEnglish (US)
Pages (from-to)159-175
Number of pages17
JournalBioDrugs
Volume13
Issue number3
StatePublished - 2000

Fingerprint

Cytomegalovirus Infections
Cytomegalovirus
Transplants
Ganciclovir
valacyclovir
Nucleic Acid Hybridization
Therapeutics
Superinfection
Subunit Vaccines
Passive Immunization
Acyclovir
Organ Transplantation
Coinfection
Reverse Transcription
Antiviral Agents
Disease Progression
Immunoglobulins
Vaccination
Transplant Recipients
Morbidity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Current management strategies for the treatment and prevention of cytomegalovirus infection in solid organ transplant recipients. / Abu-Nader, Rima; Patel, Robin.

In: BioDrugs, Vol. 13, No. 3, 2000, p. 159-175.

Research output: Contribution to journalArticle

@article{4bb31a15cd104edaa71ec8585513c938,
title = "Current management strategies for the treatment and prevention of cytomegalovirus infection in solid organ transplant recipients",
abstract = "Cytomegalovirus (CMV) infection in solid organ transplantation is associated with significant morbidity and mortality. Primary infection, secondary infection or superinfection may occur in this setting. Progression to disease may ensue with development of symptoms, with or without organ involvement. The mainstay of treatment of CMV disease is intravenous ganciclovir. Aside from protective organ matching and use of CMV-seronegative blood products, methods of preventing CMV infection and disease include passive immunization with immunoglobulins, vaccination, and prophylaxis with antiviral agents such as aciclovir, oral or intravenous ganciclovir, and oral valaciclovir. A promising subunit vaccine is currently being investigated. Pre-emptive therapy is a form of prevention that is based either on the early detection of CMV or targeting of transplant recipients with risk factors for CMV. New sensitive laboratory assays, including the pp65 antigenaemia assay, qualitative, quantitative and reverse-transcription polymerase chain reaction assays, hybridization assays, and nucleic acid sequence-based assays have the ability to detect early CMV replication before disease becomes evident. These assays are being used as prospective surveillance tests, with pre-emptive therapy initiated when they become positive or demonstrate an increasing titre.",
author = "Rima Abu-Nader and Robin Patel",
year = "2000",
language = "English (US)",
volume = "13",
pages = "159--175",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Current management strategies for the treatment and prevention of cytomegalovirus infection in solid organ transplant recipients

AU - Abu-Nader, Rima

AU - Patel, Robin

PY - 2000

Y1 - 2000

N2 - Cytomegalovirus (CMV) infection in solid organ transplantation is associated with significant morbidity and mortality. Primary infection, secondary infection or superinfection may occur in this setting. Progression to disease may ensue with development of symptoms, with or without organ involvement. The mainstay of treatment of CMV disease is intravenous ganciclovir. Aside from protective organ matching and use of CMV-seronegative blood products, methods of preventing CMV infection and disease include passive immunization with immunoglobulins, vaccination, and prophylaxis with antiviral agents such as aciclovir, oral or intravenous ganciclovir, and oral valaciclovir. A promising subunit vaccine is currently being investigated. Pre-emptive therapy is a form of prevention that is based either on the early detection of CMV or targeting of transplant recipients with risk factors for CMV. New sensitive laboratory assays, including the pp65 antigenaemia assay, qualitative, quantitative and reverse-transcription polymerase chain reaction assays, hybridization assays, and nucleic acid sequence-based assays have the ability to detect early CMV replication before disease becomes evident. These assays are being used as prospective surveillance tests, with pre-emptive therapy initiated when they become positive or demonstrate an increasing titre.

AB - Cytomegalovirus (CMV) infection in solid organ transplantation is associated with significant morbidity and mortality. Primary infection, secondary infection or superinfection may occur in this setting. Progression to disease may ensue with development of symptoms, with or without organ involvement. The mainstay of treatment of CMV disease is intravenous ganciclovir. Aside from protective organ matching and use of CMV-seronegative blood products, methods of preventing CMV infection and disease include passive immunization with immunoglobulins, vaccination, and prophylaxis with antiviral agents such as aciclovir, oral or intravenous ganciclovir, and oral valaciclovir. A promising subunit vaccine is currently being investigated. Pre-emptive therapy is a form of prevention that is based either on the early detection of CMV or targeting of transplant recipients with risk factors for CMV. New sensitive laboratory assays, including the pp65 antigenaemia assay, qualitative, quantitative and reverse-transcription polymerase chain reaction assays, hybridization assays, and nucleic acid sequence-based assays have the ability to detect early CMV replication before disease becomes evident. These assays are being used as prospective surveillance tests, with pre-emptive therapy initiated when they become positive or demonstrate an increasing titre.

UR - http://www.scopus.com/inward/record.url?scp=0034086250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034086250&partnerID=8YFLogxK

M3 - Article

C2 - 18034522

AN - SCOPUS:0034086250

VL - 13

SP - 159

EP - 175

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 3

ER -